查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1789415

CAR-T细胞疗法市场：以标靶抗原、依治疗应用、依地区划分

CAR T Cell Therapy Market, By Targeted Antigen, By Therapeutic Application, and By Region
出版日期: | 出版商: Coherent Market Insights | 英文 222 Pages | 商品交期: 2-3个工作天内

价格
简介目录

CAR-T细胞疗法市场规模预计在2025年为39.9亿美元，预计到2032年将达到150.6亿美元，2025年至2032年的复合年增长率为20.9%。

报告范围 报告详细信息
基准年 2024 2025年的市场规模 39.9亿美元
效能数据 2020-2024 预测期 2025-2032
预测期：2025-2032年 20.90% 2032年预测 150.6亿美元

嵌合体抗原受体 (CAR) T 细胞疗法是一种利用免疫 T 细胞来摧毁癌症的免疫疗法。 CAR T 细胞疗法也被称为基于细胞的基因疗法，因为它涉及 T 细胞的基因改造。在嵌合体抗原受体 (CAR) T 细胞疗法中，T 细胞透过一种称为白血球溶解的程序从人体中提取。然后，透过连接特定的嵌合体抗原受体 (CAR) 基因对其进行修饰，因此被称为 CAR T 细胞。修饰后的细胞会持续生长，然后被输注到人体。不同类型的 CAR T 细胞疗法针对特定类型的癌症进行客製化。 CAR T 细胞会根据每位患者的情况进行定制，并被输注到血液中。 CAR T 细胞疗法是一种新型的抗癌基因疗法。目前正在进行各种临床和临床前测试，以研究各种 CAR T倡议疗法针对特定癌症的安全性和有效性。此外，一些政府宣传活动美国疾病管制与预防中心 (CDC)宣传活动的教育活动，正在进行中，以提高大众对癌症的认识。

市场动态

预计在预测期内，市场主要企业越来越多地采用产品核可等有机策略，将推动市场成长。例如，2022年5月，全球医疗保健公司诺华公司（Novartis AG）的Kymriah（tisagenlecleucel）CAR-T细胞疗法获得美国食品药物管理局（FDA）核准，用于治疗復发或难治性滤泡性淋巴瘤成年患者。核准基于一项II期临床试验，其中68%的患者反应良好。

本次调查的主要特点

  • 本报告对全球 CAR T 细胞疗法市场进行了详细分析，展示了 2025 年至 2032 年期间的市场规模（十亿美元）和年复合成长率（CAGR%），以 2024 年为基准年。
  • 它还强调了各个领域的潜在商机，并说明了该市场有吸引力的投资提案矩阵。
  • 它还提供了有关市场驱动因素、限制因素、机会、新产品发布和核准、市场趋势、区域前景以及主要企业采用的竞争策略的主要考察。
  • 它根据公司亮点、产品系列、关键亮点、财务表现和策略等参数概述了全球 CAR T 细胞疗法市场的主要企业。
  • 本报告的见解将使负责人和企业经营团队能够就未来的产品发布、规模扩大、市场扩张和行销策略做出明智的决策。
  • 全球 CAR T 细胞疗法市场报告针对该行业的各个相关人员，包括投资者、供应商、产品製造商、经销商、新进业者和金融分析师。
  • 相关人员将透过全球 CAR T 细胞疗法市场分析中使用的各种策略矩阵更轻鬆地做出决策。

目录

第一章：调查目标和先决条件

  • 调查目的
  • 先决条件
  • 简称

第二章 市场展望

  • 报告描述
    • 市场定义和范围
  • 执行摘要
  • 一致的机会图（COM）

第三章：市场动态、法规与趋势分析

  • 市场动态
    • 驱动程式
    • 抑制因素
    • 市场机会
  • 影响分析
  • 市场趋势
  • 收购与合作场景
  • 监管情景
  • 管道分析
  • PEST分析
  • 波特分析

4. 2020 年至 2032 年全球 CAR-T 细胞治疗市场（以目标抗原）

  • 介绍
  • CD19
  • BCMA
  • HER2
  • GD2
  • CD20
  • CD22
  • CD30
  • CD33
  • HER1
  • 其他（CLDN18等）

5. 全球CAR-T细胞疗法市场（依治疗应用），2020-2032

  • 介绍
  • 急性淋巴性白血病
  • 慢性淋巴性白血病
  • 瀰漫大B细胞淋巴瘤（DLBCL）
  • 滤泡性淋巴瘤
  • 套细胞淋巴瘤
  • 多发性骨髓瘤
  • 神经胶母细胞瘤
  • 肉瘤
  • 神经母细胞瘤
  • 急性骨髓性白血病
  • 乳癌
  • 胰臟癌
  • 肝细胞癌
  • 大肠直肠癌
  • 其他（胃癌等）

6. 2020 年至 2032 年全球 CAR-T 细胞治疗市场（按地区）

  • 介绍
  • 北美洲
    • 美国
    • 加拿大
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 阿根廷
    • 其他拉丁美洲
  • 欧洲
    • 英国
    • 德国
    • 义大利
    • 法国
    • 西班牙
    • 俄罗斯
    • 其他欧洲国家
  • 亚太地区
    • 中国
    • 印度
    • 日本
    • 东南亚国协
    • 澳洲
    • 韩国
    • 其他亚太地区
  • 中东
    • 海湾合作委员会国家
    • 以色列
    • 其他中东地区
  • 非洲
    • 北非
    • 中部非洲
    • 南非

第七章 竞争态势

  • Bristol-Myers Squibb Company
  • Johnson & Johnson Services, Inc.
  • Novartis AG
  • CARsgenTherapeutics Co.,Ltd.
  • Aurora Biopharma
  • Legend BIoTech
  • Gilead Sciences, Inc.
  • Pfizer Inc.
  • bluebird bio, Inc.
  • Sorrento Therapeutics, Inc.
  • Mustang Bio
  • Fate Therapeutics

第 8 章 章节

  • 调查方法
  • 关于出版商
简介目录
Product Code: CMI102

Car T Cell Therapy Market is estimated to be valued at USD 3.99 Bn in 2025 and is expected to reach USD 15.06 Bn by 2032, growing at a compound annual growth rate (CAGR) of 20.9% from 2025 to 2032.

Report Coverage Report Details
Base Year: 2024 Market Size in 2025: USD 3.99 Bn
Historical Data for: 2020 To 2024 Forecast Period: 2025 To 2032
Forecast Period 2025 to 2032 CAGR: 20.90% 2032 Value Projection: USD 15.06 Bn

Chimeric antigen receptor (CAR)-T cell therapy is a type of immunotherapy which uses immune T cells to destroy cancer. CAR T cell therapy is also called as cell based gene therapy, as it involves gene altering in T cells. For chimeric antigen receptor (CAR)-T cell therapy, T cells are extracted from human body using a procedure called leukapheresis. Then after extraction, T cells are altered by adding the gene for the specific chimeric antigen receptor (CAR) and hence they are called as CAR T cells. After the alteration, the cells are kept to grow and then are infused into human body. Different type of CAR T cell therapy are made to fight specific type of cancer. CAR- T cells are customized for different patients and then infused in blood. CAR T cells therapy is used as a novel gene therapy to fight cancer. Different clinical and preclinical studies are going on to study the safety and efficacy of various CAR-T cell therapies for specific cancer. Moreover, several governments are taking initiatives such as campaigns to spread the awareness of cancer for example educational campaign by Centers for Disease Control and Prevention (CDC).

Market Dynamics

Increasing adoption of organic strategies by key players in market such as product approval is expected to drive market growth over the forecast period. For instance, in May 2022, Novartis AG., one of the global healthcare company, received the U.S. Food and Drug Administration approval for Kymriah (tisagenlecleucel) CAR-T cell therapy for the treatment of adult patients with relapsed or refractory follicular lymphoma. The approval is based on phase II clinical trial, evaluated with 68% of positive response from the patients.

Key features of the study

  • This report provides in-depth analysis of the global CAR T cell therapy market, and provides market size (USD Bn) and compound annual growth rate (CAGR%) for the forecast period 2025-2032, considering 2024 as the base year.
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
  • It profiles key players in the global CAR T cell therapy market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies.
  • Key companies covered as a part of this study include Bristol-Myers Squibb Company, Johnson & Johnson Services, Inc., Novartis AG, CARsgenTherapeutics Co.,Ltd, Aurora Biopharma, Legend Biotech, Gilead Sciences, Inc., Pfizer Inc., bluebird bio, Inc., Sorrento Therapeutics, Inc., Mustang Bio, Fate Therapeutics among other prominent players.
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
  • The global CAR T cell therapy market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global CAR T cell therapy market.

Market Segmentation

  • Global CAR T Cell Therapy Market, By Targeted Antigen
    • CD19
    • BCMA
    • HER2
    • GD2
    • CD20
    • CD22
    • CD30
    • CD33
    • HER1
    • Others (CLDN18, etc.)
  • Global CAR T Cell Therapy Market, By Therapeutic Application
    • Acute Lymphocytic Leukemia
    • Chronic Lymphocytic Leukemia
    • Diffuse Large B-cell Lymphoma (DLBCL)
    • Follicular Lymphoma
    • Mantle Cell Lymphoma
    • Multiple Myeloma
    • Glioblastoma
    • Sarcoma
    • Neuroblastoma
    • Acute Myeloid Leukemia
    • Breast Cancer
    • Pancreatic Cancer
    • Hepatocellular Carcinoma
    • Colorectal Cancer
    • Others (Gastric Cancer, etc.)
  • Global CAR T Cell Therapy Market, By Region
    • North America
    • U.S.
    • Canada
    • Latin America
    • Brazil
    • Argentina
    • Mexico
    • Rest of Latin America
    • Europe
    • Germany
    • U.K.
    • Spain
    • France
    • Italy
    • Russia
    • Rest of Europe
    • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
    • Middle East
    • GCC Countries
    • Israel
    • Rest of Middle East
    • Africa
    • South Africa
    • North Africa
    • Central Africa
  • Company Profiles
    • Bristol-Myers Squibb Company
    • Johnson & Johnson Services, Inc.
    • Novartis AG
    • CARsgenTherapeutics Co., Ltd.
    • Aurora Biopharma
    • Legend Biotech
    • Gilead Sciences, Inc.
    • Pfizer Inc.
    • bluebird bio, Inc.
    • Sorrento Therapeutics, Inc.
    • Mustang Bio
    • Fate Therapeutics

Table of Contents

1. Research Objectives and Assumptions

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Purview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Market Snapshot, By Targeted Antigen
    • Market Snapshot, By Therapeutic Application
    • Market Snapshot, By Region
  • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
    • Drivers
    • Restraints
    • Market Opportunities
  • Impact Analysis
  • Market Trends
  • Recent Developments
  • Acquisitions and Partnerships Scenario
  • Regulatory Scenario
  • Pipeline Analysis
  • PEST Analysis
  • Porter's Analysis

4. Global CAR T Cell Therapy Market, By Targeted Antigen, 2020 - 2032, (USD Bn)

  • Overview
    • Market Share Analysis, 2025 and 2032 (%)
    • Y-o-Y Growth Analysis, 2021 - 2032
    • Segment Trends
  • CD19
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • BCMA
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • HER2
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • GD2
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • CD20
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • CD22
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • CD30
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • CD33
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • HER1
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Others (CLDN18, etc.)
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

5. Global CAR T Cell Therapy Market, By Therapeutic Application, 2020 - 2032, (USD Bn)

  • Overview
    • Market Share Analysis, 2025 and 2032 (%)
    • Y-o-Y Growth Analysis, 2021 - 2032
    • Segment Trends
  • Acute Lymphocytic Leukemia
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Chronic Lymphocytic Leukemia
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Diffuse Large B-cell Lymphoma (DLBCL)
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Follicular Lymphoma
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Mantle Cell Lymphoma
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Multiple Myeloma
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Glioblastoma
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Sarcoma
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Neuroblastoma
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Acute Myeloid Leukemia
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Breast Cancer
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Pancreatic Cancer
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Hepatocellular Carcinoma
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Colorectal Cancer
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Others (Gastric Cancer, etc.)
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

6. Global CAR T Cell Therapy Market, By Region, 2020 - 2032, (USD Bn)

  • Introduction
    • Market Share Analysis, By Region, 2025 and 2032 (%)
    • Y-o-Y Growth Analysis, For Regions, 2021-2032
    • Regional Trends
  • North America
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Targeted Antigen, 2020 - 2032, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Therapeutic Application , 2020 - 2032, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Bn)
      • U.S.
      • Canada
  • Latin America
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Targeted Antigen, 2020 - 2032, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Therapeutic Application , 2020 - 2032, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Bn)
      • Brazil
      • Mexico
      • Argentina
      • Rest of Latin America
  • Europe
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Targeted Antigen, 2020 - 2032, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Therapeutic Application , 2020 - 2032, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Bn)
      • UK
      • Germany
      • Italy
      • France
      • Spain
      • Russia
      • Rest of Europe
  • Asia Pacific
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Targeted Antigen, 2020 - 2032, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Therapeutic Application , 2020 - 2032, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Bn)
      • China
      • India
      • Japan
      • ASEAN
      • Australia
      • South Korea
      • Rest of Asia Pacific
  • Middle East
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Targeted Antigen, 2020 - 2032, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Therapeutic Application , 2020 - 2032, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Bn)
      • GCC
      • Israel
      • Rest of Middle East
  • Africa
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Targeted Antigen, 2020 - 2032, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Therapeutic Application , 2020 - 2032, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Bn)
      • North Africa
      • Central Africa
      • South Africa

7. Competitive Landscape

  • Bristol-Myers Squibb Company
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Johnson & Johnson Services, Inc.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Novartis AG
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • CARsgenTherapeutics Co.,Ltd.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Aurora Biopharma
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Legend Biotech
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Gilead Sciences, Inc.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Pfizer Inc.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • bluebird bio, Inc.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Sorrento Therapeutics, Inc.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Mustang Bio
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Fate Therapeutics
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies

8. Section

  • Research Methodology
  • About Us